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A NUMBER of receptors for growth factors and differentiation
antigens have been found to be secreted or released by
cells. Following mononuclear cell (MNC) activation and
interleukin-2 receptor (IL-2R) expression, a soluble form
of the a-chain of IL-2R (sIL-2R) is released. The sIL-2R
has been shown to be present in the culture supernatants
of activated MNCs as well as in normal sera and, in higher
amounts, in sera from subjects affected by several diseases
including neoplastic, infectious and autoimmune ones,
and in sera from transplanted patients suffering allograft
rejection. The blood sIL-2R levels depend on the number
of producing cells and the number of molecules per cell,
so that sIL-2R blood values may represent an index of the
number and the functional state of producing cells, both
normal and neoplastic. Thus, monitoring of the immune
system, mostly T-cells and haematological malignancies
might be targets for the measurement of sIL-2R. Since
many conditions may influence sIL-2R production, little
diagnostic use may result from these measurements. How-
ever, since blood sIL-2R levels may correlate with disease
progression and/or response to therapy, their measurement
may be a useful index of activity and extent of disease.
The precise biological role of the soluble form of the IL-2R
is still a matter of debate. However, we know that in-
creased sIL-2R levels may be observed in association with
several immunological abnormalities and that sIL-2R is
able to bind IL-2. It is conceivable then that in these
conditions the excess sIL-2R released in vivo by activated
lymphoid cells or by neoplastic cells may somehow re-
gulate IL-2-dependent processes. On the other hand, it
cannot exclude that sIL-2R is a by-product without bio-
logical significance. Finally, it is puzzling that in many
conditions in which an increase of blood sIL-2R values
has been observed, MNCs display a decreased in vitro
capacity to produce sIL-2R. These seemingly contrasting
findings are discussed in the light of the data showing that
sIL-2R production correlates with IL-2 production.
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Interleukin-2
In 1976, the presence of a T-cell growth
promoting activity in the supernatants of activated
T-cell cultures was reported. Many laboratories
have since contributed to the characterization of
this lymphokine, now designated IL-2. IL-2 is the
most .well-defined and characterized interleukin
because of its pivotal role in the generation of
immune response and because of its biological
property of maintenance of T-cell proliferation in
vitro, which has resulted in considerable effort being
devoted to its purification and characterization.
IL-2 induces T-cell proliferation in an autocrine and
paracrine manner and provides a means by which
T-cells can be clonally expanded in vitro. The
nucleotide sequence encoding IL-2, the genomic
structure and the amino acid sequence giving rise
to IL-2 activity have all been established. IL-2 is a
single peptide of 15.5 kDa, encoded by a gene on
the long arm of chromosome 4, produced by T-cells
(most CD4, but also CD8) and natural killer (NK)
cells. In vitro IL-2 synthesis is induced by a variety
of stimuli, besides specific antigens, including
antibodies reacting with cell surface molecules
involved in activation pathways and nonspecific
activating substances such as lectins. The activity
of IL-2 is not confined to T-cells; it can act as a
growth and differentiation factor for B-cells and
,NK cells and can activate macrophages. In
transgenic mice constitutively producing high
levels of IL-2, the major effect appears to be on the
production of NK cells. 1-4
Recent advances, derived from studies in the
mouse, have demonstrated that functional subsets
of cells with otherwise indistinguishable surface
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phenotypes can be defined by the patterns of
cytokines produced. That has allowed the delinea-
tion of two subsets of CD4/ T-cells in the mouse:
T-helper (Thl)-cells, involved in delayed type
hypersensitivity (DTH), which secrete IL-2 and
interferon-gamma (IFN-q:) and Th2-cells, involved
in B-cell activation, which produce IL-4, IL-5 and
IL-6, but not IL-2 and IFN-q:. Recent reports from
several laboratories studying T-cell clones from
individuals whose immune systems are actively
engaged by antigens (e.g. subjects affected by
allergies or infectious diseases), suggest that
functional subsets of CD4/ T-cells exist also in
man. This analysis has been extended to CD8+
T-cell clones which can similarly be divided into
functional subsets based on the patterns of cytokine
production.
>7
In peripheral T-cells, IL-2 induction depends on
a series of requirements, including specific, i.e.
T-cell receptor (TCR)-mediated and nonspecific
signals. The antigen, recognized via the TCR, has
to be presented in the form of peptides bound to
the antigen-binding groove of the class II major
histocompatability complex (MHC) on the surface
of an antigen presenting cell, which delivers
accessory signals to the T-cell. Triggering of the
TCR/CD3 complex via an appropriate class
11-molecule antigenic peptide combination is
coupled to phosphoinositol hydrolysis and Ca2+
mobilization. A highly cooperative interaction
between various nuclear factors, each of which
follows a different activation schedule, has to occur
to allow activity of the enhancer of the IL-2 gene,
thus leading to IL-2 production. More than five
sequence motifs to which functionally relevant
nuclear proteins bind have been identified in the 5’
flanking region of the IL-2 gene. Analysis of
deletion mutants suggests that all the protein-
binding sites must be occupied to allow activity of
the IL-2 enhancer. Signals that activate only one of
the enhancer elements will not give rise to IL-2
transcription.-10
The Interleukin-2 Receptor
To exert its biologic effects, IL-2 must interact
with a specific membrane IL-2 receptor. In contrast
to other hormone-mediated systems, cellular
activation is a prerequisite for the induction of both
the ligand (IL-2) and its receptor (IL-2R), the latter
being expressed rapidly at the cell surface in a
time-dependent and heterogeneous manner. High-,
intermediate- and low-affinity forms of the IL-2R
11-14 exist, with different dissociation constants.
The high-affinity IL-2R is composed of at least
two non-covalently linked chains, IL-2Ra and
1L-2Rfl, with molecular weights of 55 and 75 kDa,
respectively. Analysis of the nucleotide sequences
encoding IL-2Ra and IL-2Rfl has shown that the
two genes are unrelated. The a-chain of IL-2R
consists of an extracellular domain of 219 amino
acids, a transmembrane region of 19 amino acids
and a short cytoplasmic domain of 13 amino acids.
IL-2Ra was formerly called Tac antigen from
’T-activated’, since the monoclonal antibody
(mAb) that recognizes this molecule was initially
determined to recognize an activation antigen on
T-cells. Actually, the IL-2R a-chain is termed CD25
antigen according to the cluster of differentiation
(CD) nomenclature of surface molecules of
haemopoietic cells. In humans, the IL-2R a-chain
is encoded by a single gene on chromosome 10 and
is induced and expressed only after T-cell, B-cell or
monocyte activation. This specific feature of CD25
provides investigators with a unique marker of
immune system activation before the appearance of
other cell surface determinants and well before
lymphocyte proliferation. Mitogen stimulation in
vitro induces a peak level of approximately 60 000
site/cell within 48-72 h but the number of receptors
then progressively declines.
1>2
The IL-2R fl-chain, whose gene is located on
chromosome 22, consists of a 214 amino acid
extracellular domain, a 25 .amino acid transmem-
brane region and a 286 amino acid cytoplasmic tail.
The longer cytoplasmic domain of the fl-chain
suggests that this chain is involved in efficient signal
transduction. Homology comparisons have re-
vealed that the IL-2R fl polypeptide corresponds to
a member of a novel cytokine receptor superfamily,
the haemopoietin receptor family or type-1 cytokine
receptor family, which includes the membrane
receptors for IL-3, IL-4, IL-6, IL-7, erythropoietin,
granulocyte-macrophage colony stimulating factor
(GM-CSF), prolactin and growth hormone. 11-4’22’23
The intermediate aflCinity receptor contains only
the 75 kD IL-2R fl-chain, while the low affinity
receptor is comprised of the 55 kD IL-2R a-chain.
Without the presence of the a-chain, to achieve cell
activation IL-2 must be present at concentrations
ten- to 100-fold above those required for a
physiological response. The rate of association of
IL-2 with, and dissociation from, the a-chain is very
rapid, whereas the association rate with the fl-chain
alone is slower and the dissociation rate very slow.
Therefore, expression of the high aflqnity receptor
endows the cell with a receptor provided with a fast
on rate and a slow off rate, thus ensuring that IL-2
is avidly bound, retained and internalized at
physiological concentrations. However, the fi-chain
of IL-2R is also able to mediate the internalization
of bound IL-2 in the absence of the a-chain. In fact,
it has been shown that the IL-2R fl-chain mediates
the initial proliferative response of resting T-
lymphocytes and large granular lymphocytes and
the initial phase of induction of lymphokine
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activated killer (LAK) and NK activities. Further-
more, the binding of IL-2 to the p75 /-chain
induces the expression of the IL-2R0 gene and the
CD25 antigen in these cells. Thus, the inducible
nature of IL-2R0 gene expression contributes to a
transient display of a high-affnity receptor, while
the IL-2Rfl protein appears to play a major role in
growth signal transduction, although this ability
probably requires the coexpression of a novel IL-2R
component termed the "c-chain. 11-14’24-28
In fact, a third subunit of human IL-2R has
recently been identified. It is a p64 molecule named
the r-chain, which coprecipitates with the fl-chain
and IL-2 in immunoaffnity columns conjugated
with TU11, an mAb specific for the IL-2R
fl-chain. The IL-2R "c-chain, whose gene has been
cloned, belongs itself to the type-1 cytokine
receptor family, participates in the formation of the
high- and intermediate-affnity IL-2R and it has
been shown to be essential for the receptor-
mediated internalization of IL-2. In fact, analysis of
the IL-2R chains cDNAs in sublines derived from
murine fibroblastoid cell lines, showed that
coexpression of 0-, fl-, "c-chains and fl-, "c-chains is
required in order to obtain high- and intermediate-
affnity binding, respectively, of IL-2 by transfected
cells. Moreover, transfected cells expressing 0-,
fl- and r-chains have been shown to internalize IL-2
more effciently than cells bearing only fl- and
"c-chains, while cells expressing only 0- and fl-chains
have rarely been shown to be able to internalize
IL-2 although they have the ability to bind IL-2
with greater affinity than intermediate-affnity
receptor bearing cells. In addition, with the use of
various methods including coimmunoprecipitation
analysis, radiolabelled IL-2 cross-linking and flow
cytometric resonance energy transfer measurement,
additional proteins such as class-I MHC and
intercellular adhesion molecules ICAM-1 were
found to be associated with IL-2R. Furthermore,
the intracellular domain of IL-2R/ is associated
with a tyrosine kinase, lck, which, after IL-2R
activation, phosphorylates several specific proteins
involved in cell proliferation14’23’29’3 (Table 1).
The development of anti-Tac and anti-Mik-l
mAb to the 0- and fl-subunits of IL-2R,
respectively, together with Northern blot analysis
using chain-specific probes, has resulted in the
delineation of IL-2R expression on different cell
types. By using these mAbs, a marked difference
in expression of IL-2R subunits on blood CD4+
and CD8 + T-cells has been demonstrated between
adults and newborns. In the adult blood, reciprocal
expression of IL-2R0 and IL-2Rfl has been
observed in CD44- and in CD84- T-cells. Some
CD44- T-cells expressing IL-2R0 have been
detected, but IL-2Rfl, CD44- cells were few.
On the other hand, CD84- T-cells express
Table 1. Human IL-2R
Chain
IL-2R IL-2Rfl IL-2R
Molecular 55 75
weight (kDa)
Amino acid residues 251 525
(’mature’ proteins)
Chromosome 10p 14 15 22q 11.2 12
IL-2R +
(low affinity)
IL-2R +
(intermediate affinity)
IL-2R + +
(high affinity)
40
347
ND
+
+
Approximate molecular weight of mature proteins (kDa).
The high-affinity receptor is unusual among the cytokine
receptors because it consists of three distinct subunits, instead
of two subunits.
For references see text.
significant IL-2Rfl, but little IL-2R0. Although the
reason is still unknown, it is probably because the
differences in the IL-2R subunits expression are
related to the biological role of T-cell subsets. Both
CD44- and CD84- T-cells from the newborns,
which probably consist mainly of naive popula-
tions, showed only negligible expression of IL-2R
subunits. IL-2R subunits have appeared to be
preferentially expressed on CD44- and CD84-
T-cells with memory phenotypes in the adult blood.
Isolated memory (CD45RO +) CD4+ and CD8 4-
T-cells, unlike naive (CD45RO--) ones, were able
to proliferate in response to exogenous IL-2 as well
as to the recall antigen. This suggests that IL-2R
subunits expressed on circulating T-cell subsets
might play an important role in eliciting a secondary
response. According to the significance of IL-2 for
T-cell growth, it is plausible to suppose that
memory T-cells could readily respond to recall
antigens, their already expressed IL-2R subunits
being largely involved in antigen-induced prolifera-
tion.
31
Finally, the ratio of low-affnity sites to
high-affnity sites is approximately 10:1 in both
resting and activated lymphocytes and in most
IL-2R expressing T-cell lines tested. The majority
of NK cells (CD16+) constitutively express the
intermediate-affinity IL-2R instead and a sub-
population of NK (CD16--) cells expresses t’he
high-affinity receptor. Human monocytes that
respond to IL-2 with induction of IL-1 mRNA
and an enhanced cytotoxic capacity, express the
/3-chain of IL-2R, but not the 0c-chain (see
below).
28,32-36
IL-2R expression is not limited to normal
mononuclear cell populations. The presence of
IL-2R has been demonstrated on the membrane of
malignant cells in Hodgkin’s disease and B- and
T-cell neoplasias. The biologic function of IL-2Ro
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on malignant cells is largely unknown, but it is
thought to involve the stimulation of cell
proliferation.
37-41
As stated for the IL-2 gene, for IL-2R0 an
interaction between various nuclear factors also has
to occur to allow the activity of the gene enhancer.
The promoter region of the IL-2R0 gene consists
of a minimum of five positive regulatory elements
and at least one negative element. IL-2 and IL-2R0
share at least one regulatory element. This datum
may explain why these two gene products are
usually coexpressed. Unlike the IL-2 gene, which is
strictly dependent on triggers from the antigen
receptor plus accessory signals, IL-2R0 is expressed
after activation with IL-1, IL-5, phorbol myristate
acetate or binding of ligands to the TCR alone,
without a requirement for second signals.
1
Soluble Interleukin-2 Receptor
In 1985 it was first observed that, after in vitro
cellular activation, not only the expected cell-
associated IL-2R, but also a soluble form of the
receptor could be found in the cell-free supernatants
of these cultures. This soluble molecule seems to
correspond to a truncated extracellular part of the
membrane bound Tac antigen, is smaller than its
cellular counterpart (45 vs 55 kDa) and retains the
ability to bind IL-2. Similarly to cellular IL-2R
expression, soluble IL-2R (sIL-2R) production
requires de novo synthesis, but not cellular
proliferation.
42
To study sIL-2R, the anti-TAC mAb and an mAb
termed 7G7/B6, which binds to the human IL-2R
at an epitope distinct from that recognized by the
anti-Tac, have been used to construct a ’sandwich’
enzyme-linked immunoasorbent assay (ELISA)
that offers a simple and rapid method for
quantitating slL-2R levels. Although both mAbs
recognize the IL-2R, anti-Tac, but not 7G7/B6,
blocks IL-2 binding and the binding of 7G7/B6 to
the IL-2R 0-chain is not blocked by anti-Tac or
IL_2.2,43
Enzymatic digestion of this molecule reveals that
it is a complex glyco’protein, containing both
N- and O-linked sugars and sialic acid residues,
similar to those previously demonstrated on the
mature cell surface IL-2R. The generation of
soluble IL-2R does not appear to be the result of
cell death with subsequent IL-2R release, since
IL-2R-positive cells killed by repetitive freezing and
thawing and placed back into culture do not release
sIL-2R.42,44
Theoretically, several mechanisms might account
for the production of slL-2R. One mechanism
refers to the possibility that separate genes encode
the secreted and cellular forms of IL-2R.
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Alternatively, both forms of the IL-2R could be the
product of the same gene via differential mRNA
splicing, giving rise to an ’anchor minus’ protein
which is then released. However, the predominant
mechanism of release appears to be, at least in
T- and B-cells, the proteolytic cleavage at the cell
surface. Since the slL-2R has been detected in the
supernatants of activated cells cultured in serum-
free media, a cellular rather than an exogenous
protease should be responsible for the release of the
soluble form of the receptor. However, the rate of
release of this molecule is in proportion to its cell
surface expression and any cell expressing the
0-chain protein seems to be capable of releasing
slL-2R. In addition, sIL-2R has not been found in
the complete absence of concurrent or temporally
related cell-surface Tac expression, although, in vivo,
cells expressing the membrane-associated molecule
might not necessarily be detected within the same
42---47 physical compartment.
Accordingly, in a recent study it was observed
that following mitogen stimulation in vitro, 25% of
CD4+ lymphocytes and 19% of CD8+ lympho-
cytes expressed CD25. Approximately 55% ofCD25
positive MNCs were CD4+ lymphocytes and 45%
were CD8+ lymphocytes. A significant correlation
was demonstrated between the membrane bound
48 IL-2R and its soluble form in supernatants.
The generation of sIL-2R is uniformly ’activa-
tion-dependent’ except in specific neoplastic condi-
tions in which the malignant phenotype is
characterized by the constitutive expression of Tac
and release of sIL-2R. Activated normal peripheral
blood MNCs (T-cells, B-cells and monocytes) as
well as certain T- and B-cell lines have all been
found to release the soluble form of the
IL_2R. 35,36,41,42,46,49
In vitro stimulation with lipopolysaccharide
initiates monocytes to produce the IL-2R light
chain. After 48 h, considerable quantities of slL-2R
are produced by activated monocytes. Since the
main portion of the receptor is present in the
cytoplasm, it is probable that in monocytes
cell-associated p55 IL-2R is not necessarily attached
to membranes, but is present in a soluble form in
the cytoplasm, presumably freshly produced with
the aim of being secreted. Incidentally, this explains
why induction of p55 IL-2R does not lead to
high-affinity binding by monocytes as observed
with T-cells: the IL-2R 0-subunit is hardly
expressed on the plasma membrane.
36
The generation of slL-2R is more rapid and
efficient in cultures stimulated with the polyclonal
activators, compared with those stimulated with
either soluble exogenous antigens or cell-associated
alloantigens. This difference is presumably related
to the precursor frequency of the cells being
activated and is in accord with previous determina-sIL-2R significance
tions of cell surface IL-2R expression after
activation with various stimuli. 42’44
In supernatants of cultured cells, slL-2R has also
been shown to be present in normal sera. The
normal levels of serum slL-2R (expressed as
arbitrary units referred to a standard preparation of
supernatants from phytohaemoagglutinin (PHA)-
stimulated lymphocytes; 3 units 1 pg of purified
protein) have been shown to range between 100 and
500 U/ml, the mean value being approximately
250 U/ml. These values are likely to reflect the
ongoing lymphocyte activation which normally
occurs upon physiological stimuli. Age-related
changes in serum slL-2R levels in otherwise healthy
subjects have been described. Initial studies
disclosed that levels of slL-2R in cord blood and
peripheral blood from normal adults were compar-
able. It is likely that cord blood sIL-2R might be
the result of lymphopoiesis or be of maternal origin
rather than of exogenous antigenic stimulation.
Subsequently, it has been found that serum slL-2R
levels are significantly higher in healthy children
younger than 6 years old than in normal adults,
gradually declining to typical adult levels by 10
years of age and then rising again in elderly persons,
suggesting a higher baseline level of immune
activation during childhood and ageing. No
significant sex-related differences have been noted.
Recently, one study performed on 228 healthy
young adult blood donors has confirmed that there
is no correlation between serum levels and the
different ages or sex of adult donors. Another study
performed on a small number of subjects has instead
demonstrated that slL-2R displays a pronounced
circadian phase-dependency.47’49-55
An immunoreactive soluble form of IL-2R has
also been found in the urine of normal individuals.
Like serum slL-2R, the urinary receptor has a
molecular weight of 40-45 kDa and specifically
binds IL-2. Moreover, the urine levels of slL-2R
correlate positively with those in the serum.
Currently available literature does not point to any
definitive conclusion about the renal handling of
slL-2R. However, the comparative data with the
fl-2 microglobulin may be consistent with the
hypothesis that slL-2R undergoes glomerular
filtration and partial tubular reabsorption as well as
the fi-2 microglobulin. On the other hand, it could
also be that slL-2R is produced, at least in part,
within the urinary tract. Indeed the finding that
glomerular mesangial cells are able to secrete IL-1
is in agreement with this hypothesis, since IL-1 is
involved in inducing the expression of the CD25
molecule on the lymphocyte surface. 1’56-58
Increased levels of the soluble form of IL-2R0
have been observed in the serum of patients with
malignant, autoimmune and allergic disorders, as
well as in subjects affected by systemic infectious.
Table 2. Diseases or states with highserum slL-2R levels
Hairy cell leukaemia
Adult T-cell leukaemia
B-cell chronic lymphocytic leukaemia
Non-Hodgkin’s lymphoma
Hodgkin’s disease
Acute lymphoblastic leukaemia
Myelodysplastic syndromes
Multiple myeloma
Acute myeloid leukaemia
Cutaneous T-cell lymphomas
Angioimmunoblastic lymphadenopathy
Lung, colon, stomach or uterine cancer
Nasopharyngeal carcinoma
Systemic lupus erythematosus
Rheumatoid arthritis
Juvenile rheumatoid arthritis
Polymyositis
Sjorgren’s syndrome
Myastenia gravis
Insulin dependent diabetes mellitus
Graves’ disease
Toxic multinodular goitre
Multiple sclerosis
Crohn’s disease
Ulcerative colitis
Coeliac disease
Sarcoidosis
IgA nephropathy
Atopic dermatitis
Psoriasis
Anaphylactic reaction to food
Systemic sclerosis
Kawasaki disease
Infectious mononucleosis
Measles
Virus hepatitis
AIDS
Plasmodium falciparum infection
Chronic hepatosplenic schistisomiasis
Strongyloidosis
Fasciolosis
Alveolar echinococcosis of the liver
Visceral leishmaniasis
Leprosy
Tubercolosis
Burn
Common variable immunodeficiency
Haemodialysis
Transplantation
For references see text.
diseases or undergoing allograft rejection (Table 2).
Although in vitro the 0-chain of IL-2R is released
from the cell membrane of activated B-cells and
monocytes by proteolytic cleavage, the amount
released has been thought to be trivial compared to
T-lymphocyte production. Thus, the presence of
the soluble form of the IL-2R 0-chain in serum has
been suggested to mostly reflect the state of T-cell
activation in these subjects. Depending on the type
of disorder and on clinical state, increased levels of
slL-2R can be detected in other body fluids as
we11.46,49,55,59-61
Although investigations of IL-2-mediated
growth effects have been focused on the interaction
of the cytokine at the cell surface receptor, it is
possible that the released receptor plays an
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immunomodulating role. Although the released
form of slL-2R is 10 kDa smaller due to lack of
transmembrane and intracytoplasmic domains, it
retains the ability to bind IL-2. In fact by affinity
chromatography, sIL-2R is capable of binding to
purified recombinant IL-2 (rlL-2). It has a similar
afffnity to the Tac surface protein, which, as
previously stated, is approximately 100- to
1 000-fold lower than the high-affnity IL-2R
complex. Experiments examining the addition of
the purified natural or synthetically generated
sIL-2R protein to in vitro 1L-2 functional assays
show inhibition of the stimulatory effects of
exogeneously added IL-2 (see below).44’49’55’60-62
Increased slL-2R Levels in
Haernopoietic Malignancies
Increased serum sIL-2R levels have been found
in a variety of lymphoproliferative and haematolo-
gic malignancies, including hairy cell leukaemia,
adult T-cell leukaemia, B-cell chronic lymphocytic
leukaemia, acute leukaemia, non-Hodgkin’s lym-
phoma, Hodgkin’s disease and myelodysplastic
syndromes. Although the increase in serum levels
may result from release by activated normal cells,
the levels are more likely to derive, in most cases,
from neoplastic cells. In fact, as discussed by Rubin
and Nelson,
49 in haemopoietic malignancies,
increased slL-2R levels are mostly indicative of a
malignant phenotype associated with deregulated or
enhanced expression of CD25. Nevertheless, in the
interpretation of these measurements, one should
consider that host cellular immune response may
contribute to the generation of slL-2R. However,
they generally correlate with disease progression
and/or with response to therapy, so that the
measurement of serum slL-2R may be a useful index
of activity and extent of the disease. 49’55’59-61
The increased serum slL-2R levels are not
specific of any haematological disorder, neverthe-
less very high levels of slL-2R (up to 50 000 U/ml)
may be considered diagnostic of hairy cell
leukaemia (HCL), in the context of the clinico-
pathological picture of the disease.
6> Similar
levels may be detectable in adult T-cell leukaemia
(ATL), but in the presence of peculiar epidemio-
logical and clinical features.41’56’67-7 Human T-
lymphotropic virus type-l-associated (HTLV-1)
ATL is a malignancy of CD4+ T-cells. The
constitutive expression of high levels of CD25 on
malignant transformed cells has proved to be an
extremely valuable phenotypic marker distinguish-
ing ATL from other histologically similar lympho-
reticular neoplasms, such as Sezary syndrome and
overexpression of the IL-2R 0-chain is considered
to be one of the characteristics of T-cells
transformed by HTLV-1. In fact, essentially all
HTLV-1 infected T-cell lines established from ATL
patients or HTLV-1 carriers, as well as the majority
of the ATL leukaemic cells, constitutively express
IL-2R0 mRNA and protein IL-2R0 overexpression
is tightly associated with T-cell immortalization
and/or activation of HTLV-1 infected T-cells.
Accordingly, very high serum slL-2R levels have
been found in this disease. Acute patients have the
highest serum levels, whereas those with smoulder-
ing disease or healthy HTLV-l-antibgdy-positive
carriers have normal to slightly elevated levels.
Intermediately elevated levels are seen in patients
with the chronic form of the disease. Moreover,
serum sIL-2R levels reflect disease activity. In fact,
these values decrease to normal when patients
respond to treatment and increase in progressive
disease. Serum sIL-2R levels appear to reflect the
total tumour burden accurately, irrespective of
circulating leukaemic cell numbers, which are
sometimes low even in the presence of significant
disease. Serial measurements of sIL-2R levels thus
seem to be a useful, non-invasive laboratory method
in the management of these patients.
As stated above, high serum slL-2R levels have
also been detected in patients with HCL,
>6 a
chronic lymphoproliferative disease of B-cell origin.
Release of the receptors by hairy cells appears to be
the most likely explanation for this finding. Serum
values fell to near the normal range in patients
responding to therapy, whereas no significant
changes have been found in patients who failed to
respond. Hence, the determination of slL-2R levels
may be important in monitoring disease activity and
response to treatment.
Most adults with B-cell chronic lymphocytic
leukaemia (B-geL)
"2-’/4 have increased serum
slL-2R levels, the higher being observed in patients
with mo}e advanced disease. Purified malignant
B-cells from such patients release slL-2R after in
vitro culture, although in some cases the membrane
receptor is not expressed on malignant cells. By
contrast, little or no detectable sIL-2R is released
by purified T-cells from these patients. The sIL-2R
in patient serum is derived largely from the
’activated’ malignant cells rather than from the
normal activated T-cells.
In children with newly diagnosed acute lympho-
blastic leukaemia,
4-9 increased values of sIL-2R
have been found, the levels being lower in
T-cell leukaemias, than in non-T, non-B cases.
Among the patients with non-T-non-B leukaemia,
higher serum receptor levels have been shown to
be associated with a poorer treatment outcome.
Further, serum slL-2R levels contributed in-
dependent prognostic information. The source of
slL-2R in patients with acute lymphoblastic
leukaemia is unknown.
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It has been observed that in patients with
non Hodgkin’s lymphoma (NHL),s1’8-82 high
serum slL-2R levels correlate with more advanced
disease and with a poorer clinical outcome. Serum
sIL-2R levels have been shown to be elevated in all
of the cases of T-cell and most of the cases of B-cell
lymphoma examined. Higher serum sIL-2R levels
are also related to an increased likelihood of
treatment failure. More importantly, the serum
sIL-2R level seems to be an independent prognostic
factor. The measurement of serum slL-2R in
children with NHL should thus improve existing
methods of risk assignment. That serum slL-2R in
,his disease is largely derived from tumour cells is
suggested by the correlation of sIL-2R levels with
tumour burden, the high levels of receptors found
in malignant serous effusions and the fact that some
lymphoma cell lines have high levels of cell-
associated IL-2R.
In adults with Hodgkin’s disease (HD),59-61’83-85
it has been found that higher serum slL-2R levels
are associated with more advanced stages of disease
and with the presence of constitutional symptoms.
Serum slL-2R levels returned to normal in patients
who responded to treatment, but persisted elevated
or increased in patients with resistant or progressive
disease. In addition, the slL-2R level may
independently predict treatment outcome. Because
the majority of Reed-Sternberg cells and their
mononuclear variants strongly express IL-2R, these
high serum levels stem at least in part from release
of the receptor by malignant cells. Therefore, serum
slL-2R levels reflect tumour burden. However,
unstimulated MNCs of patients release more slL-2R
than controls, suggesting that the host cellular
response contributes to sIL-2R production. No
difference was observed between PHA-stimulated
MNCs of patients and controls.
Significant increase of sIL-2R in a group of
patients with myelodysplastic syndromes
86 has been
described. Interestingly, six patients who had been
under treatment with recombinant GM-CSF for at
least 2 weeks, demonstrated a three- to seven-fold
increase of serum sIL-2R compared to pretreatment
levels. These data, however, cannot suggest
whether increased sIL-2R release is a primary event
due to involvement of lymphocytes in the
malignant clone or whether it results from
secondary alteration of the cytokine network.
Increased serum slL-2R levels have also been
observed in patients with multiple myeloma
87 (the
slL-2R concentration was significantly correlated
with the concentration of monoclonal immunoglo-
bulin in serum), acute myeloid leukaemias9’6
(higher levels were observed in cases with M4--M5
morphology as compared to patients with M1-M2-
M3), angioimmunoblastic lymphadenopathy
59 and
cutaneous T-cell lymphomas (CTCL).
88-9 Although
stable chronic myelogenous leukaemia91’92 is not
associated with increased serum sIL-2R, during the
blastic phase of chronic myelogenous leukaemia,
CD25 antigen is expressed on malignant cells and
elevated slL-2R levels can be detected in serum.
Rising serum sIL-2R levels antedate clinically
apparent blast crisis in this condition.
The biological role of slL-2R in haematological
malignancies needs further evaluation. However,
theoretically sIL-2R can affect a number of
IL-2-dependent functions and, thus, it might indeed
be responsible for several alterations of immune
functions commonly found in haematological
malignancies.
A finding supportive of this possibility is the
observation that an inverse relationship of serum
sIL-2R concentrations to the in vitro NK activity in
patients with HCL exists. Furthermore, lympho-
cytes of B-CCL patients with the lowest serum
sIL-2R levels show the best mitogenic response and
helper capacity. 6s’74
Finally, in patients with cutaneous T-cell
lymphoma, the decrease of NK activity correlates
with the augmentation of serum slL-2R. After a 4
day stimulation with IL-2, MNCs from CTCL-
affected patients show an increase of cytotoxic
activity similar to that of healthy donor MNCs.
Normal donor MNCs demonstrate a diminished
IL-2-induced cytotoxic activity in 25% of CTCL
sera compared to control sera, while IL-2-
dependent proliferation of 48 h PHA blasts is lower
in CTCL sera than in control sera. Enrichment of
media with exogeneous sIL-2R inhibits the
IL-2-dependent generation of cytotoxic activity and
mitogen blast proliferation suggesting that elevated
sIL-2R levels account for diminished NK activity
by neutralizing IL-2 in CTCL patients.
9
slL-2R Release in Other Malignancies
High blood levels of sIL-2R may be found in
patients with solid neoplasms. Moreover, it has
been suggested that sIL-2R levels in the blood of
patients with cancer may display a prognostic
significance, probably related to host immune
reactions rather than representing a tumour
marker.
93
High serum sIL-2R levels have been found in
patients with lung cancer94-96 of different histo-
logical type (small cell, epidermoid carcinoma,
adenocarcinoma, unclassified carcinoma). No sig-
nificant differences were found within different
histological types, nor within different disease
stages. However, it seems that slL-2R changes after
surgery have prognostic importance, compared to
the levels found before surgery. In fact in patients
affected by epidermoid carcinoma or adenocarcino-
ma, a surgery-induced increase in slL-2R levels was
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seen 7 days after surgery in most of the patients
studied. On the thirtieth day after surgery, sIL-2R
values were lower than the preoperative values in
more than half patients and greater in the remaining
ones. After a median follow-up of 10 months, the
latter group showed a significantly higher relapse
rate, thus suggesting that the persistence of
increased slL-2R levels in the postoperative
period is associated with a higher early relapse rate
in patients with operable non-small cell lung cancer.
In patients with nasopharyngeal carcinoma
97
serum sIL-2R levels have been shown to be elevated
and to correlate with clinical staging. Higher
sIL-2R levels have been observed in patients with
bone metastasis, but not in patients with intracranial
involvement. Since depressed cell-mediated immun-
ity is well-documented in patients with nasophar-
yngeal carcinoma, it has been suggested that sIL-2R
may serve as a blocking factor that competes with
IL-2 function, resulting in a decreased mitogenic
response.
Soluble IL-2R levels assessed in sera derived
from patients with non-metastatic or metastatic
breast cancer98 or from healthy controls did not
difl:er significantly from each other. When sIL-2R
levels were assessed in supernatants from mitogen-
stimulated MNCs derived from either patients or
healthy controls, healthy individuals were found to
produce sIL-2R in an amount that was significantly
higher than levels found in both patient groups, i.e.
with non-metastatic as well as with metastatic
disease under immediate cytostatic treatment.
Moreover, a significant difl:erence was found in
mitogen-stimulated sIL-2R production between
patients with or without metastases, the first group
being more depressed. Adjuvant radio- and
chemotherapy both resulted in a significant and
long-lasting depressive effect upon mitogen-
induced sIL-2R release. A strong correlation was
found between mitogen-induced sIL-2R concentra-
tions and results obtained in simultaneous experi-
ments assessing mitogenic stimulation of MNCs.
Serum levels of slL-2R have also been shown to
be significantly increased in patients aected by
cancer of the colon, stomach or uterine cervix and
metastatic cancer patients showed significantly
higher values than the non-metastatic ones. Thus,
serum slL-2R levels in non-haemopoietic mal-
ignancies may also be increased, probably as a result
of activation of the immune system in response to
cancer. Moreover, there is some evidence that
serum slL-2R levels may be an indicator of
metastasis for patients with solid turnouts.%’99
Finally, in patients with progressive metastatic
renal carcinoma, malignant carcinoma, colorectal
cancer, B-cell lymphoma or HD treated with rIL-2,
significant increases in slL-2R levels have been
observed when comparing values on day zero and
after treatment course. Interestingly, sIL-2R corre-
lated with CD25 positive blood MNCs.1’11
slL-2R Production in Autoirnmune
Diseases
Recent papers have demonstrated increased levels
of sIL-2R in the sera of patients with a variety of
autoimmune or immune-mediated diseases includ-
ing systemic lupus erythematosus, rheumatoid
arthritis, juvenile rheumatoid arthritis, poly-
myositis, Sjogren’s syndrome, myastenia gravis,
insulin-dependent diabetes mellitus, Graves’ dis-
ease, multiple sclerosis, Crohn’s disease, ulcerative
colitis, coeliac disease, sarcoidosis, IgA nephro-
pathy, atopic dermatitis and psoriasis. In most
diseases serum levels correlate with disease activity
as defined by various clinical and laboratory
parameters. These data suggest the usefulness of
measuring serum slL-2R levels in the management
of autoimmune patients.
12
However, in systemic lupus erythematosus
(SLE),
>8 it has not been possible to find any
association between serum sIL-2R and a particular
clinical manifestation. Furthermore, serum sIL-2R
levels have very frequently been found to be
increased in active as well as inactive SEE. In fact,
the concentration of sIL-2R was higher in inactive
SLE patients than in normal controls and was
significantly increased in active as compared to
inactive SLE patients. When patients with active
disease were followed up serially, it was found that
the slL-2R concentration fell when the disease
became inactive. However, there was no statistically
significant association between slL-2R and the
grades of disease activity, neither did sIL-2R levels
parallel indicators of serological disease activity
such as anti-DNA antibodies. On the whole these
data suggest that lymphocyte activation may still be
present even though the disease is considered
inactive under clinical criteria and that sIL-2R and
autoantibodies measure different facets of immune
system activation.
Serum levels in rheumatoid arthritis (RA)
9-16
patients are significantly raised compared to patients
with non-inflammatory joint disease and to
age-matched, disease-free controls. Moreover, with-
in the RA patients, synovial fluid slL-2R levels are
significantly higher than serum levels, indicating
that proliferating synovial tissue is the probable
source of the sIL-2R detected in the circulation. In
sequential studies of individual patients during
spontaneous remission, the serum slL-2R levels
correlate with disease activity. Serum concentra-
tions of sIL-2R are correlated with erythrocyte
sedimentation rates and C-reactive protein levels.
Interestingly, the reduction of slL-2R levels
towards control values precedes clinical remission,
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suggesting that this is not a secondary event
reflecting clinical improvement, but is more likely
to be related to the activation of immunopathogenic
mechanisms that produce inflammation. Consistent
with this hypothesis is the high spontaneous
production of slL-2R in freshly isolated MNCs
from RA synovial exudate. Similar levels can only
be achieved by autologous blood MNC populations
after stimulation with mitogens. Of great interest is
the highly significant correlation observed between
synovial fluid levels of sIL-2R and IL-lfl, since IL-1
has been implicated as a pathogenic mediator in
articular diseases. The correlation noted could then
result from the action of IL-1 as a cofactor in CD25
expression. Moreover, since synovial fluid slL-2R
levels are significantly elevated when compared
with those of other osteoarthritic conditions, this
suggests that their determination may be useful in
a clinical situation where a definitive diagnosis has
not yet been possible. In contrast, PHA-stimulated
MNCs derived from patients with RA produced
similar amounts of slL-2R as compared to
PHA-stimulated MNCs derived from healthy
controls. No significant correlation of slL-2R levels
in sera with slL-2R concentrations in supernatants
of mitogen-stimulated MNC has been found.
Spontaneous, i.e. non-mitogen-stimulated, produc-
tion of slL-2R by MNCs in culture was below the
detection limit in patients with RA as well as in
controls. Furthermore, the relationship between
synovial fluid MNC production of sCD8, sCD4 and
slL-2R has been examined. The results reveal two
populations of patients. Synovial fluid MNCs from
one population produced high levels of sCD8 and
relatively low levels of sIL-2R, whereas the other
population produced low levels of sCD8 and high
levels of slL-2R. Taken together, the data indicate
that the size or activity of the CD8+ T-cell
populations in the rheumatoid synovium is
inversely related to the activity of CD25 positive
MNCs. The observed results could be the
expression of fluctuations in the activity of the two
different populations of MNCs, one of which,
largely CD8+, mediates remission, while a
population expressing high levels of CD25 mediates
an inflammatory response resulting in an increase
in disease activity. Synovial fluid levels of sCD4
correlate positively with slL-2R levels, but no
correlation has been found with sCD8 levels. The
levels of serum sCD4 in these patients closely follow
the slL-2R levels, possibly indicating that they may
be derived from the same cellular subsets. In fact,
studies of synovial fluid MNCs show that the release
of these two molecules occur at a similar rate.
However, the serum sIL-2R level in RA probably
reflects activation of underlying immunopathogenic
mechanisms and appears to be an excellent monitor
of clinical disease activity. More importantly rising
levels may also predict exacerbation of disease
activity.
In juvenile rheumatoid arthritis (JRA)
117 in-
creased slL-2R levels have also been observed. The
highest values have been seen in patients with
systemic JRA and in patients with clinically active
disease, but serum sIL-2R levels were elevated in
all subgroups of clinically active patients compared
to controls.
In polymyositis118’9 the combination of elevated
slL-2R and sCD8 levels has been associated with
active muscle inflammation. Serial measurements
show a rise in serum sIL-2R and sCD8 levels before
clinical and biochemical relapse.
In Sjogren’s syndrome
12 the serum levels of
slL-2R progressively increase from patients with
disease confined to the exocrine glands to patients
with extraglandular manifestations without pseudo-
lymphoma or lymphoma and, finally, to patients
with lymphoproliferative diseases. Therefore, high
serum slL-2R levels seem to indicate the pro-
gression of disease to extraglandular involvement
and to pseudolyphoma or lymphoma. Moreover,
further studies are needed to obtain a clear-cut
demonstration that monitoring of serum sIL-2R
provides a useful predictive index for the
development of lymphomas which frequently
complicate the disease course.
In myastenia gravis
2 the slL-2R titre is high in
a significant number of patients, especially when
tested before thymectomy. Patients with a severe
form of the disease present the highest slL-2R
serum levels and a significant and progressive
decline of slL-2R titres is observed after thy-
mectomy, which is well-correlated to clinical
improvement in individual patients. These findings,
taken together, suggest that the evaluation of
slL-2R in the serum may represent a good marker
of disease severity and of the effect of thymectomy
in the follow-up of individual patients.
In insulin dependent diabetes mellitus
(IDDM)21’122 newly diagnosed patients’ sera,
higher levels of sIL-2R in comparison with sera
from healthy subjects have been observed. After a
time interval from the beginning of symptoms of
type 1 diabetes and exactly 6 months after clinical
diagnosis of the disease, the patients maintained
levels which were high with respect to healthy
subjects and were almost identical to the ones at
onset. In contrast mitogen stimulated MNCs from
both newly diagnosed and long-term IDDM
patients produce low amounts of sIL-2R. The
combined data clearly establish that MNCs from
newly diagnosed IDDM patients in vivo are activated
and have the capacity to express and release
increased amounts of slL-2R, but in vitro, with
appropriate stimulation, they have decreased
capacity to produce such receptors and have
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defective IL-2 production. The phenomenon of
decreased production of IL-2 and sIL-2R in vitro is
also partially present in long-term IDDM patients
and may be of great interest. In this connection, the
theory of a generic exhaustion phenomenon (see
concluding remarks) cannot be applied to long-term
type 1 diabetic patients. When all of these data are
considered, the IL-2 and sIL-2R defects in type 1
diabetes seem to be linked to the immunogenetic
profile of the disease.
Serum sIL-2R levels have been observed to be
significantly increased in newly diagnosed Graves’s
disease
123-126 patients as compared with controls.
The slL-2R levels were higher in patients with
active infiltrative ophthalmopathy than in those
without eye symptoms. In patients treated with
methimazole for at least 12 months, sIL-2R levels
were normalized in the majority of patients without
ophthalmopathy, but not in those with ophthalmo-
pathy. Furthermore, a correlation has been found
between sIL-2R levels and anti-TSH receptor
antibodies, but not with other immune parameters
examined. However, it has been suggested that the
level of slL-2R is not only dependent on
immunological conditions, but also on thyroid
hormone status. In fact, when thyroid hormone is
administered to subjects in remission from Graves’
disease and in normal controls, the sIL-2R levels
significantly increase in both groups. Moreover, the
mean level of sIL-2R in patients with toxic
multinodular goitre125’26 is also significantly higher
than in normal controls. Thus, sIL-2R levels are
higher in the sera of subjects with elevated levels
of thyroid hormone, irrespective of the cause of
hyperthyroidism. These high serum sIL-2R con-
centrations might merely be the result of an
accelerated turnover of T-cell membranes due to a
hypermetabolic state. This phenomenon prevents
the use of sIL-2R as a reliable marker of
autoimmune activation in hyperthyroid conditions.
Elevated serum slL-2R levels have been reported
in patients with multiple sclerosis (ms)
127-130 of the
chronic progressive type, during a period of relative
disease quiescence. This finding, taken in conjunc-
tion with that of elevated serum IL-2 levels and the
evidence of elevated and prolonged expression of
cell-bound IL-2R, indicates that an activated
cellular immune state parallels the progression of
the demyelinating process in MS. Soluble IL-2R
levels in both serum and cerebrospinal fluid have
been found to be higher in patients with relapsing
MS than in patients with disease quiescence.
Furthermore, slL-2R levels change with high
sensitivity in parallel with disease activity. Levels
of sIL-2R in steroid-treated chronic progressive
patients were markedly lower than in untreated
chronic progressive patients and were comparable
to healthy controls.
Levels of serum sIL-2R have been shown to be
significantly higher in Crohn’s Disease (Cd) and
ulcerative colitis (UC).
3>3s Intestinal mucosal
MNCs always produced more sIL-2R than
peripheral cells. Spontaneous sIL-2R production by
mucosal MNCs is significantly elevated in Cd, but
not in UC supernatants. A positive correlation has
been found between blood sIL-2R and spontaneous
production by intestinal MNCs of Cd patients and
surgical control patients, whereas UC plasma
slL-2R correlated with spontaneous production by
peripheral MNCs. Upon stimulation with mitogens,
Cd, normal controls and diverticulitis lamina
propria MNCs reached similar maximal slL-2R
secretion levels, while UC lamina propria mono-
nuclear cells secreted significantly less sIL-2R. On
the other hand, it has been found that endoscopical
mucosal biopsy specimens from patients with
inflammatory bowel diseases contained significantly
increased amounts of slL-2R. Furthermore, the
highest concentrations were consistently found in
the most inflamed biopsy specimens. In Cd,
increased blood sIL-2R levels have been detected
in patients with more clinically severe disease. A
progressive increase in sIL-2R levels has been noted
to correlate with endoscopic measurement of
disease extent, while sIL-2R levels did not correlate
with other markers of systemic lymphocyte
activation, suggesting possible local mucosal
production. Sequential determinations in individual
patients revealed a good correlation between
sIL-2R, clinical course and laboratory measure-
ments of disease activity including the C-reactive
protein and the erythrocyte sedimentation rate.
More importantly, elevated levels of sIL-2LR
preceded clinical relapse of asymptomatic patients.
Concentrations of slL-2R in the serum of patients
with coeliac disease
136 are significantly raised in
patients with untreated disease compared with
treated patients and controls. Longitudinal studies
in individual coeliac patients showed that serum
sIL-2R fell following commencement of a gluten-
free diet. Gluten challenge of treated coeliac
patients for 1 week resulted in a significant increase
in serum sIL-2R, which returned to prechallenge
levels within 4 weeks of recommencement of a
gluten-free diet. These data suggest that serum
sIL-2R levels in patients with coeliac disease reflect
specific immunological activation in response to
gluten ingestion. Measurement of serum sIL-2R
may therefore be useful in the assessment of
response to treatment in patients with coeliac
disease.
Elevated levels of sIL-2R have been found in
patients with active pulmonary sarcoidosis137’38 as
compared to normal controls. Furthermore, serum
sIL-2R levels have been shown to fall after clinical
improvement following corticosteroid treatment,
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suggesting that measurements of serum sIL-2R
could prove useful in monitoring disease activity.
Moreover, it has been observed that the levels of
sIL-2R in the serum of sarcoidosis cases with
bilateral hilar lymphoadenopathy (BHL) are signifi-
cantly higher than those of cases without BHL.
In patients with IgA nephropathy
139 serum levels
of sIL-2R were significantly higher than in controls
and were higher in the subgroup of patients with
episodic macrohaematuria. Since the presence of red
blood cells in the urinary sediment has been shown
to be closely related to serum slL-2R levels,
measurement of sIL-2R may provide a good marker
for disease activity.
Serum slL-2R levels are also significantly
elevated in subjects with atopic dermatitis14 and
psoriasis
4 as compared to healthy controls.
Furthermore, sIL-2R levels in atopic dermatitis
patients showed a significant correlation with IgE
levels and body surface involvement and long-
itudinal studies have shown that measurement of
serum sIL-2R may have a prognostic value.
Significant elevation of slL-2R was also observed
in sera from children with histories of anaphylactic
reaction to food,
141 as compared to non-allergic
controls. Finally, also in systemic sclerosis142-144 and
in Kawasaki disease
4s high levels of serum sIL-2R
have been reported.
It is intriguing to note that in two groups of
subjects, i.e. healthy old individuals and young
HLA-B8,DR3 positive subjects, known to show an
increased incidence of autoimmune diseases or
phenomena, a decreased in vitro production of
slL-2R by PHA-stimulated MNCs has been
observed. In fact, after in vitro stimulation, cultures
from both HLA-B8,DR3 positive individuals and
elderly subjects are characterized by hyposecretion
of IL-2 and slL-2R as compared with cultures from
HLA-B8,DR3 negative subjects and young in-
dividuals, respectively. By contrast, serum slL-2R
levels are increased in these subjects. 146’47
In summary, the discussed findings suggest that
in autoimmune diseases sIL-2R levels may represent
a good marker of disease activity which indirectly
reads the ongoing activation of immunoreactive
cells which are involved in the pathogenetic events
of these immunomediated conditions.
With regard to the degree of activation required
to increase serum levels of slL-2R, serum sIL-2R
levels have recently been measured in healthy
subjects after immunization with keyhole limpet
haemocyanin (KLH). Despite induction of strong
antibody responses, KLH immunization did not
result in consistent elevations of sIL-2R levels. This
datum suggests that inflammatory diseases in which
elevated sIL-2R levels have been noted, involve
more extensive stimulation of immune cells, either
in number or in degree.
14s
Although it has been suggested that sIL-2R has
a role in down-regulating 1L-2 dependent re-
sponses, it remains to be defined whether
circulating sIL-2R intervenes in inducing the
immunologic dysfunctions commonly found in
autoimmune diseases. In this regard, it has to be
remembered that sIL-2R in synovial fluids has been
demonstrated to compete with cell-associated
receptors for available IL-2. In fact sIL-2R levels in
synovial fluid correlate with functional inhibition of
IL-2-driven responses assessed as the inhibition of
an in vitro response to optimal concentration of
rIL_2.19
slL-2R Release in Infectious Diseases
Viruses, bacteria and parasites may actively
engage the immune system by inducing a strong
activation, thus it is not surprising that in infectious
diseases it is possible to observe an increase of
slL-2R blood levels. Moreover, little clinical use
may result from sIL-2R measurement in these
diseases, except perhaps in HIV infection.
In infectious mononucleosis59’6’149 analysis of
serum sIL-2R demonstrated significantly elevated
levels as compared to normal controls. Increased
levels of sIL-2R were correlated with increased
percentages of activated CD8+ T-cells. These
values tend to decrease progressively in relation to
the reduction of activated CD8+ and symptom
relief. Patients with X-linked lymphoproliferative
syndrome and virus-associated haemophagocytic
syndrome, two syndromes associated with severe
acute Epstein Barr virus infections, demonstrated
the most dramatic increase in sIL-2R levels.
During measles,s the levels of serum sIL-2R
increase before the onset of the rash and remain
elevated for at least 4 weeks. Peak numbers of
peripheral blood IL-2R-expressing lymphocytes
appear coincidentally with the onset of the rash and
remain for approximately 10 days.
In hepatitis B virus
15>53 infection increased
values of sIL-2R have been found during both acute
liver damage and active chronic phase. Serum
slL-2R has been measured in patients with acute
type B hepatitis, patients with chronic type B
hepatitis and controls. All patients with acute type
B hepatitis presented levels significantly higher than
those of normal controls or of patients with chronic
type B hepatitis. Serial follow-up showed that
serum levels of sIL-2R tended to return to normal
2-4 months after onset of acute hepatitis along with
the normalization of alanine aminotransferase.
Patients with chronic type B hepatitis also had
significantly higher levels of sIL-2R that varied
considerably with liver flogosis, i.e. significantly
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lower levels were detected in patients with chronic
infection who had no evidence of active liver
disease. In chronic infection, in response to therapy
with prednisone and/or interferon, serum slL-2R
fell significantly and a significant correlation
between serum sIL-2R and alanine amino transfer-
ase levels has been observed. High slL-2R levels
have also been observed during hepatitis A
infection, while lower values have been seen during
hepatitis C infection, lsl
Many reports show that serum sIL-2R levels are
increased in human immunodeficiency virus (HIV)
seropositive and AIDS-affected5’1s4-164 subjects and
are inversely correlated with both relative and
absolute numbers of CD4+ T-cells and with the
CD4/CD8 ratio, although it has to be pointed out
that this relation probably takes place only late after
seroconversion. Soluble IL-2R levels of seroposi-
tive subjects have been demonstrated to be
predictive for development of AIDS, to correlate
with response to therapy and to increase as a direct
effect of HIV infection and not only as a
consequence of opportunistic infections. Finally,
serum sIL-2R does not correlate with either other
serum markers of HIV infection (i.e. neopterin and
fl2-microglobulin) or cell membrane expression of
CD25, that is decreased in HIV infection. In one
study, however, a significant association between
blood slL-2R and neopterin levels has been
observed.
A significant increase of serum slL-2R levels,
which reflects chronic activation of the immune
system, has been demonstrated in patients with
systemic parasitic diseases. In fact, elevated slL-2R
levels has been observed in the serum of patients
with plasmodium falciparum infection, chronic
hepatosplenic schistosomiasis, strongyloidosis, fas-
ciolosis, alveolar echinococcosis of the liver and
visceral leishmaniasis.
65-8 Conversely, this par-
ameter is not significantly increased in localized
parasitic disease, particularly in intestinal schistoso-
miasis. The circulating levels of sIL-2R appear to
reflect, the extent as well as the severity of the
diseases. It has been suggested that in alveolar
echinococcosis of the liver and in chronic
hepatosplenic schistosomiasis, both characterized
by the development of liver granulomas, slL-2R
could be released by activated macrophages rather
than by T-lymphocytes. Incidentally, as discussed
by Bresson-Hadni et al. this might also be true
for other granulomatous diseases such as sarcoid-
osis. Sera from patients with visceral leishmaniasis
at the moment of the diagnosis, during the course
of the disease and after clinical recovery, have been
analysed for the concentration of serum slL-2R.
The results show that slL-2R is a marker of disease
activity, since it is in high concentration at the
beginning of infection and returns to the normal
range following successful chemotherapy. At the
same time as serum analysis for sIL-2R, MNCs of
patients were stimulated with PHA or antigen and
supernatant tested for IL-2 and IFN-q: production.
Data demonstrate that there is an inverse relation
between concentration of IL-2 and IFN-, in the
supernatants and slL-2R secretion in the sera.
In leprosy9’17 a moderate increase of serum
slL-2R levels has been found in untreated
lepromatous patients, as opposed to the decreased
values found in tuberculoid patients. Highly
elevated levels were associated with reversal
reaction and, to a lesser extent, with erythema
nodosum leprosum. Thus, the potential for
developing DTH reaction to M. Leprae antigens is
not suflqcient to induce elevated serum sIL-2R levels
by itself. The high serum slL-2R levels found in
patients with reversal reaction instead provides
indirect evidence for the association of elevated
slL-2R with accelerated or profound DTH reaction.
Treatment with corticosteroids was invariably
associated with a concurrent drop in serum slL-2R
levels, thus providing an objective measure of
compliance. During erythema nodosum there is a
transient rise in agalactosyl IgG and this increase
parallels an increase in blood slL-2R. Finally,
increased levels of slL-2R have been observed in
patients affected by tuberculosis.
171
slL-2R Release in Transplanted
Patients
Activation of T-lymphocytes in response to
alloantigens is a central component of the rejection
process after organ transplantation. Thus, in the
absence of infection, one could assume that
increased slL-2R levels might be a tool to evaluate
the presence of rejection activity.
12
Indeed, as regards slL-2R production in
kidney
:s-v6 recipients, it has been demonstrated
that serum levels of sIL-2R are significantly higher
in patients suffering renal allograft rejection as
compared to patients with stable graft function and
that the serial evaluation of serum slL-2R increases
the specificity and sensitivity of the test. Further-
more, it has been observed that during rejection
episodes urine slL-2R levels are increased in a
pattern undistinguishable from those of serum
levels. The increase of serum slL-2R has also been
shown to be comparable to the rise in serum
creatinine values which is observed in rejection
episodes, the predictive value of the combined tests
being superior to either alone. Moreover, it has
been observed that the raise in serum slL-2R levels
is higher during rejection episodes than in the case
of other forms of allograft dysfunction, e.g.
infections or cyclosporin A (CsA) toxicity. In fact
nephrotoxicity as a result of CsA treatment has been
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shown to be a cause of a slight elevation in SIL-2R compared to sIL-2R levels from all other patients.
levels. However, concerning infectious diseases, However, an increase of slL-2R shortly after heart
patients with cytomegalovirus infections have been transplantation has been shown to correlate with
shown to have sIL-2R levels equivalent to those the development of coronary arteriopathy and with
found in patients undergoing rejection. Again, the mortality during long-term follow-up. Finally, a
combination of slL-2Rand creatinineassays greatly correlation has been observed between serum
enhances the predictive value of either test alone sIL-2R levels and graft rejection after heart-lung
for distinguishing acute graft rejection from and lung transplants. In fact, the relative sIL-2R
infection. However, the administration of anti-T- levels in patients with heart-lung and lung
cell antibodies to patients with kidney allograft transplants could help to differentiate between
rejection is followed by a rise in plasma slL-2R, infection and rejection. In a prospective blind study
Recently, the clinical utility of monitoring sIL-2R sIL-2R was markedly elevated during rejection.
levels in renal transplant recipients has been Interestingly, slL-2R levels seemed to be related to
appraised by a multicentre study. A significant the quantity of allograft tissue, with mean sIL-2R
increase of serum sIL-2R levels was observed in the levels during rejection episodes in single-lung
presence of rejection episodes as compared to recipients being roughly half the level seen in the
prerejection values and to values observed in stable recipients of two lungs (bilateral lung or heart-lung
patients, respectively. Moreover, slL-2R concentra- transplants).
tions were significantly higher in cadaver recipients Although these results are suggestive, more
than in living renal donor recipients, not only at clinical experience with sIL-2R is needed to make
the time of rejection, but also prior to rejection and a final statement on the utility of sIL-2R as a
early posttransplantation. Finally, slL-2R levels rejection marker at least in liver, heart and lung
may also be influenced by therapy, since patients transplants.
who received antilymphocyte antibody induction
therapy showed higher values.
177
slL-2R Production in Other Diseases
Both serum and biliary sIL-2R levels are
significantly higher in patients undergoing acute as Following mytogen stimulation, lymphocytes
well as chronic liver
17-18 rejection as compared to from immunosuppressed burn18s’1 patients exhibit
the control group. Serum and biliary slL-2R a reduced number of CD25 positive cells. In
increase have been shown to occur before the contrast, sera from burn patients contain markedly
diagnosis of rejection was possible based on clinical elevated levels of sIL-2R that are inversely
symptoms and conventional laboratory tests, but proportional to the density of CD25 antigens
biliary values appeared to be more specific and expressed on the surface of mytogen-activated
sensitive for prediction of graft outcome, although lymphocytes. In recovering subjects a progressive
serum sIL-2R rises earlier. Biliary slL-2R levels rose reduction of serum slL-2R, which paralleled the
24 h after serum levels, suggesting that lymphocyte restoration of lymphocyte reactivity to mytogen
activation occurs outside the graft and then stimulation, has been observed. Soluble IL-2R was
activated cells localize to the graft. Although significantly higher in sera from burn patients who
infections may also cause an increase in serum did not survive than in sera from patients who
slL-2R levels, these have always been shown to be survived. Throughout the postburn period a
lower than those observed in rejection episodes, significant proportion of patients studied also
Finally, it has been shown that biliary and serum demonstrated increasing levels of serum IL-2. In
slL-2R levels are significantly lower in patients with this period in vitro IL-2 production and sIL-2R
complications other than acute graft rejection and secretion in patient cultures were significantly
in patients undergoing chronic rejection and that reduced as compared to the controls. These
serum slL-2R levels are inversely related to the observations suggest that in the burn patients
duration of the disease, altered synthesis and/or secretion of the soluble
Experience with sIL-2R assays in heart and form of sIL-2R may be regulated to IL-2 content.
lung
18-184 transplant patients is limited. Single In sera from patients with common variable
determinations of slL-2R levels in both serum and immunodeficiency (CVI)
7 levels of soluble CD8,
plasma have instead not proved to be useful in soluble CD25 and fl2-microglobulin were raised
detecting heart transplantation rejection. In fact no significantly above levels in normal sera. They
correlation has been found between slL-2R and correlated with the extent of the defects in the
histological findings of graft rejection in en- B-lymphocytes assessed in vitro, as well as with the
domyocardial biopsies. When serial measurements clinical severity of the disease. The selective release
of serum slL-2R were performed, a significant of these molecules into sera may indicate that
difference was observed only when mean sIL-2R abnormal cellular activation occurs in most CVI
levels of patients presenting a severe rejection were patients.
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Patients on chronic haemodialysis
188 had in-
creased plasma sIL-2R. The reduced kidney
excretion in chronic renal failure could be a simple
explanation. Haemodialysis patients present lym-
phopenia and higher CD4/CD8 ratios, CD16 counts
and sIL-2R concentrations as compared to controls.
A significant inverse correlation was found between
sIL-2R concentration and lymphocyte count and
between slL-2R concentration and CD4/CD8 ratio.
An increase of sIL-2R concentration due to
abnormal T-cell preactivation in haemodialysis
patients with non-reused cuprophan membranes
could perhaps contribute to cell immunity impair-
ment through IL-2 binding and inhibition of T-cell
activation.
Soluble IL-2R has also been measured in the
serum of patients with liver cirrhosis, patients with
obstructive jaundice,
189 patients with alcoholic liver
disease without evidence of cirrhosis, healthy
persons and patients with unrelated diseases. In
patients with cirrhosis and obstructive jaundice
sIL-2R was significantly increased as compared to
healthy subjects and patients with unrelated
diseases. No difference was found between patients
with cirrhosis due to alcohol abuse and chronic
hepatitis B. In obstructive jaundice, slL-2R
correlated with alkaline phosphatase as a marker of
cholestasis. These data show that in spite of the
apparent depressed cellular immune defence, both
in liver cirrhosis and obstructive jaundice, there is
a general activation of the immune system.
Concluding Remarks
A number of receptors for growth factors and
differentiation antigens have been found to be
released or secreted by different cells. Little is
known, however, about the function of these
soluble molecules during cell growth and differ-
entiation. Although investigations of cytokine-
mediated growth effects have focused almost
exclusively on the interaction of molecules at the
cell surface, it is possible that released molecules
that can potentially bind ligands and/or act to
transmit important signals between cells might
function in promoting or regulating these pro-
cesses. 44’114-116’118’133’190 In this regard, as stated
earlier, it is of note that the released form of IL-2R,
which is 10kDa smaller due to lack of transmem-
brane and intracytoplasmic domains, still retains the
ability to bind IL-2 with an aflqnity similar to the
membrane-bound form of the Tac molecule,
although it is approximately 100- to 1 000-fold
lower than the high-aflqnity IL-2R complex. Indeed,
as discussed in the present review, experiments
examining the addition of exogenous sIL-2R to in
vitro IL-2 functional assays show inhibition of the
stimulatory effects of IL-2. Further, immunologic
assessment of patients after therapeutic infusion of
high doses of IL-2, which is invariably accompanied
by a marked increase in serum slL-2R levels, reveals
a decreased responsiveness in vivo as well as in vitro
to recall antigens.9’9’9 The ability of this
molecule to bind to IL-2 suggests then a potential
role in the regulation of IL-2-dependent cell
function by competing with cellular IL-2R for the
growth factor IL-2, thus down-regulating the
immune response. However, it has to be stressed
that these findings may be due to the use of
supraphysiological doses of slL-2R and IL-2,
respectively, such as that currently used in in vitro
studies and for therapeutic purposes. This may
activate negative feedback circuits, thus explaining
the functional defect observed.
Alternatively, the rapid increase in slL-2R after
cellular activation has occurred, may represent the
means, by a proteolytic cleavage mechanism, for
activated cells to reduce surface receptor density
below a critical threshold level, thus preventing an
ongoing, perhaps undesirable, response. Another
possibility is that sIL-2R acts as a binding protein,
effectively prolonging the half-life of IL-2, with
low-aflqnity slL-2R delivering IL-2 to high-afFinity
membrane receptors and/or serving to locally
confine the effects of IL-2, hence, keeping immune
responses local.42’44 Finally, it should not be
forgotten that the presence of slL-2R in the serum
might be an epiphenomenon simply reflecting the
activation of the immune system. Indeed, we have
observed that, after MNC stimulation with PHA,
there is a significant correlation between the levels
of sIL-2R in supernatants at 24h and the
proliferative response at 48 h (Fig. 1). We can
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FIG. 1. Correlation between slL-2R levels measured at 24 h of culture and
proliferative response to PHA determined at 48 h of culture (r 0.52,
p 0.03). M NCs from 16 healthy subjects were divided into two aliquots.
The first one was processed to produce slL-2R, the second one was
stimulated for 48 h with PHA and proliferation assayed. Experiments were
performed as previously described.147 Soluble L-2R values are expressed
as unit/ml. Proliferative responses are expressed as mean Adpm which is
equal to the dpm of the cells in the mitogen-containing medium minus the
dpm of the cells in the medium without mitogens.
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FIG. 2. Correlation between slL-2R (U/ml) and IL-2 (pg/ml)levels in
cultures from 20 healthy subjects (r= 0.67, p 0.0009). Experiments
were performed as previously described.146’147 IL-2 values were
quantified by commercial ELISA.
conclude that sIL-2R does not impair MNC
mitogen responsiveness, at least at physiological
concentrations in vitro. More probably sIL-2R
release is expression of the IL-2 driven MNC
activation, as depicted in Fig. 2, which shows that
there is a linear correlation between IL-2 and
slL-2R production at 24h by in vitro PHA-
stimulated MNCs.
However, the blood slL-2R levels depend on the
number of producing cells and on the number of
molecules per cell and therefore slL-2R blood
values represent an index of the number and
functional state of producing cells, although in
some conditions no correlation has been found
between IL-2R expression by circulating cells (as
detected by cytometric techniques) and slL-2R
serum levels. This discrepancy may reflect the
different dynamics of the two forms of the receptor
or, most probably, it is due to the local production
of sIL-2R which may constitute an important
source of serum sIL-2R.
172 Moreover, metabolic
alterations, particularly impairments of renal
function, can affect the level of serum sIL-2R. In
fact, impaired renal function elevates serum sIL-2R,
as this molecule is likely to be actively transported
into the urine, s6’58 The serum slL-2R level then is
a sensitive and quantitative marker of circulating
MNC activation and may also reflect immune
activation in other tissues or fluid compartments.
The basal serum slL-2R levels may therefore be
considered to be a reflection of the baseline level of
immune activation under normal physiologic
stimuli and immunological monitoring of the
immune system, mainly of T-cell activation (but
also of monocytes in granulomatous disorders),
might be the target for the measurement of slL-2R.
On the other hand, the increased concentration
of slL-2R observed in lymphoid malignancies
appears to reflect tumour burden, so that
measurement of sIL-2R serum levels has been
proved to be helpful in estimating prognosis and
diagnosing relapse. In other diseases like allograft
rejection, infections, autoimmune diseases and
non-haematological malignancies, the elevation of
slL-2R is likely to indicate the immune system
activation in response to antigenic challenge by
infectious agents, autoantigens and cross-reacting
determinants and malignant cell antigens, respec-
tively and, therefore, it can be successfully used to
monitor disease progress and therapy effects.
Finally, it is puzzling that in many conditions in
which an increase of blood sIL-2R values has been
observed, MNCs display a decreased in vitro capacity
to produce slL-2R. This is indeed the case in
autoimmune diseases tested in this regard, burns,
some kind of malignancies, as well as in healthy
elderly subjects and young healthy HLA-B8,DR3
positive individuals. 98’122’146’4"’185’8
However, in these conditions, more complex
abnormalities of the IL-2/IL-2R system may be
described, consisting of a defect in IL-2 release by
mitogen-activated mononuclear cells, increased
expression of CD25 in unstimulated peripheral
blood lymphocytes from patients with active
disease, low expression of C25 in mitogen-
stimulated cells from the same patients, and high
serum levels of IL-2 correlating with some indices
Of activity. 10’98’122’4’47’185’18’ 92
As IL-2 induces soluble and membrane-bound
IL-2R0 both in vitro and in vivo, it cannot be ruled
out that the observed changes in slL-2R levels are
secondary to the changes in IL-2 concentration
and/or production (Fig. 2).’1
Concerning the defective in vitro IL-2 production
it has been suggested that precommitment and
preactivation of peripheral T-cells in vivo result in a
transient exhaustion of IL-2 secretion. As an
alternative to the exhaustion theory, it is conceiv-
able that production of IL-2 by a subpopulation of
in vivo-activated lymphocytes elicits feedback regula-
tion pathways that attempt to restore the
homeostasis of the IL-2/IL-2R system by non-
specifically suppressing IL-2 production.
However, our studies on immune function of
HLA-B8,DR3 positive and elderly individuals
suggest that these two groups of subjects are low
responders. In fact findings such as high serum
sIL-2R levels and an increased number of CD25 +
circulating lymphocytes which may be suggestive
of a high responder status, are instead an expression
of the relative inability of these subjects to remove
immunological stimuli from the body. This, in our
opinion, is responsible for a prolonged stimulation
and may lead to the persistence of signs of immune
system activation at least in these subjects and in
autoimmune patients.
14<4’92q94
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